Keyphrases
Cancer Patients
100%
Clear Cell Renal Cell Carcinoma (ccRCC)
100%
Methylation Markers
100%
LAD-1
100%
GREM1
100%
Gene Promoter Methylation
100%
Marker Panel
100%
Confidence Interval
44%
Prognostic Model
22%
Kaplan-Meier Curve
11%
Microarray
11%
Cox Proportional Hazards Model
11%
Epigenetic Modification
11%
Log-rank Test
11%
Outcome Prediction
11%
Poor Survival
11%
Promoter Methylation
11%
Metastatic Renal Cell Carcinoma (mRCC)
11%
Quantitative Methylation-specific PCR (Q-MSP)
11%
Model Combining
11%
Methylome
11%
Massively Parallel Sequencing
11%
Molecular Markers
11%
Predictive Ability
11%
Cancer Genome Atlas
11%
Carcinoma Cell Lines
11%
Cause-specific Survival
11%
5-aza-2′-deoxycytidine
11%
Akaike Information Criterion
11%
RNA Expression Profiling
11%
Methyl-binding Domain
11%
Promising Biomarkers
11%
Renal Carcinoma Cells
11%
INIS
patients
100%
cancer
100%
genes
100%
kidneys
100%
panels
100%
promoters
100%
methylation
100%
carcinomas
90%
data
10%
curves
10%
information
10%
design
10%
biological markers
10%
dna
10%
rna
10%
hazards
10%
pcr
10%
statistics
10%
capacity
10%
deoxycytidine
10%
Biochemistry, Genetics and Molecular Biology
Methylation
100%
Cancer Cell
100%
Gene Promoter
100%
LAD1
100%
NEFH
100%
Polymerase Chain Reaction
14%
Promoter Region
14%
Epigenetics
14%
Microarrays
14%
RNA
14%
Genetic Marker
14%
Methylome
14%
Decitabine
14%
Binding Domain
14%
Cause Specific Survival
14%
Medicine and Dentistry
Cancer Cell
100%
Clear Cell Renal Cell Carcinoma
100%
Methylation
100%
Gene Promoter
100%
Clear Cell
100%
Biological Marker
11%
Proportional Hazards Model
11%
Polymerase Chain Reaction
11%
Kaplan Meier Method
11%
Molecular Marker
11%
Log Rank Test
11%
Promoter Region
11%
Decitabine
11%
The Cancer Genome Atlas
11%
Cause Specific Survival
11%
Renal Cell Carcinoma Cell Line
11%
Akaike Information Criterion
11%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Renal Cell Carcinoma
100%
Biological Marker
11%
Molecular Marker
11%
Akaike Information Criterion
11%
Decitabine
11%
Cause Specific Survival
11%